AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16120455 — intervention group
Group type: COMPARATOR
Intervention: Direct-mail communications without phone intervention (placebo messages)
Number of subjects: 424
Study 12770794 — intervention group
Group type: EXPERIMENTAL
Intervention: HFE S65C mutation
Number of subjects: 218
Study 12770794 — intervention group
Group type: EXPERIMENTAL
Intervention: HFE C282Y mutation
Number of subjects: 218
Study 12770794 — intervention group
Group type: EXPERIMENTAL
Intervention: HFE mutations (C282Y, H63D, S65C)
Number of subjects: 218
Study 11263272 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlicin injection (60 mg/day for 10 days)
Number of subjects: 34
Study 11263272 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerine (control group)
Number of subjects: 34
Study 8644686 — intervention group
Group type: EXPERIMENTAL
Intervention: Crackers with cream cheese
Number of subjects: 15
Study 8644686 — intervention group
Group type: COMPARATOR
Intervention: Crackers with nonfat cream cheese
Number of subjects: 15
Study 8644686 — intervention group
Group type: COMPARATOR
Intervention: Crackers alone
Number of subjects: 15
Study 8644686 — intervention group
Group type: COMPARATOR
Intervention: Nothing
Number of subjects: 15
Study 2000846 — intervention group
Group type: EXPERIMENTAL
Intervention: Imprisonment longer than 28 days
Number of subjects: 600
Study 2000846 — intervention group
Group type: EXPERIMENTAL
Intervention: Household crowding
Number of subjects: 600
Study 2000846 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct smoking at home
Number of subjects: 600
Study 2000846 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive smoking at home
Number of subjects: 600
Study 6337669 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection sclerotherapy
Number of subjects: 108
Study 6337669 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (medical measures, modified splenectomy, oesophagogastric devascularization)
Number of subjects: 108
Study 30576449 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Chromoendoscopy (VCE)
Number of subjects: 60
Study 30576449 — intervention group
Group type: COMPARATOR
Intervention: Conventional Chromoendoscopy (CE)
Number of subjects: 60
Study 30566441 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported Self-help Preventive Cognitive Therapy (S-PCT)
Number of subjects: 248
Study 30566441 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 248
Study 27172435 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment with clomiphene from PPCOS II trial (N = 187)
Number of subjects: 329
Study 27172435 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment with clomiphene after oral contraceptive pretreatment in OWL PCOS trial (N = 142)
Number of subjects: 329
Study 27172435 — intervention group
Group type: COMPARATOR
Intervention: Deferred clomiphene treatment preceded by lifestyle modification (N = 129)
Number of subjects: 329
Study 27172435 — intervention group
Group type: COMPARATOR
Intervention: Deferred clomiphene treatment preceded by combined treatment (N = 129)
Number of subjects: 329
Study 24589316 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet treatment
Number of subjects: 33
Study 24589316 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 21515562 — intervention group
Group type: EXPERIMENTAL
Intervention: 532 nm continuous‐wave Nd:YAG laser pretreatment
Number of subjects: 30
Study 21515562 — intervention group
Group type: COMPARATOR
Intervention: Standard pulsed 1064 nm Nd:YAG laser iridotomy
Number of subjects: 30
Study 21515562 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (sequential and standard treatment)
Number of subjects: 30
Study 20211953 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Number of subjects: 1006
Study 20211953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1006
Study 17588715 — intervention group
Group type: EXPERIMENTAL
Intervention: TV annuloplasty with the MC3 ring
Number of subjects: 136
Study 16182733 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-cm 4.8-F double J stent with anti-reflux device (group A)
Number of subjects: 44
Study 16182733 — intervention group
Group type: COMPARATOR
Intervention: 14-cm 4.8-F double J stent without anti-reflux device (group B)
Number of subjects: 44
Study 16182733 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 44
Study 14644054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral and family treatment components
Number of subjects: 0
Study 14644054 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment approach
Number of subjects: 0
Study 10379447 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-impregnated central venous catheter
Number of subjects: 165
Study 10379447 — intervention group
Group type: COMPARATOR
Intervention: Control catheters (no antimicrobial activity)
Number of subjects: 165
Study 8884873 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 IU/ml in a bicarbonate buffer dissolved in 0.9% benzyl alcohol (approximately 1.37 mg/ml)
Number of subjects: 18
Study 8884873 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.9 IU/ml in a phosphate buffer dissolved in 1.5% benzyl alcohol (approximately 2 mg/ml)
Number of subjects: 18
Study 8884873 — intervention group
Group type: EXPERIMENTAL
Intervention: 11.7 IU/ml in a phosphate buffer dissolved in 1.5% benzyl alcohol (approximately 4 mg/ml)
Number of subjects: 18
Study 8884873 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.9 IU/ml
Number of subjects: 18
Study 8884873 — intervention group
Group type: EXPERIMENTAL
Intervention: 11.7 IU/ml
Number of subjects: 18
Study 8884873 — intervention group
Group type: COMPARATOR
Intervention: 4 IU/ml
Number of subjects: 18
Study 1676318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (1 mg, two 0.5 mg tablets and one placebo tablet within 27 hours after delivery, then placebo twice daily for 14 days)
Number of subjects: 272
Study 1676318 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine (2.5 mg, two placebo tablets within 27 hours after delivery, then 2.5 mg twice daily for 14 days)
Number of subjects: 272
Study 1676318 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 272
Study 6500678 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary sodium reduction (from approximately 110 to 40 mEq per day)
Number of subjects: 33
Study 29721010 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ihPAS
Number of subjects: 20
Study 29721010 — intervention group
Group type: COMPARATOR
Intervention: Control ihPAS
Number of subjects: 20
Study 28073985 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vaccination during pregnancy (part of a randomized controlled trial of influenza vaccination)
Number of subjects: 3483
Study 26186449 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit smoothie
Number of subjects: 81
Study 26186449 — intervention group
Group type: COMPARATOR
Intervention: Mineral water
Number of subjects: 81
Study 23360656 — intervention group
Group type: EXPERIMENTAL
Intervention: Clary oil
Number of subjects: 34
Study 23360656 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender oil
Number of subjects: 34
Study 23360656 — intervention group
Group type: COMPARATOR
Intervention: Almond oil (control)
Number of subjects: 34
Study 21092293 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - specific PFTs selected according to protocol
Number of subjects: 179
Study 21092293 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - all PFTs ordered by lung specialist
Number of subjects: 179
Study 17993594 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (2 microg/l)
Number of subjects: 12
Study 17993594 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 12
Study 17993594 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitro-L-arginine (NLA, 10 mM)
Number of subjects: 12
Study 17993594 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan + NLA
Number of subjects: 12
Study 17993594 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 12
Study 16731213 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 792
Study 16731213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 792
Study 12601840 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of serum activin A
Number of subjects: 58
Study 12601840 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of serum inhibin A
Number of subjects: 58
Study 12601840 — intervention group
Group type: EXPERIMENTAL
Intervention: Activin A at cut-off value of 1.7 MoM
Number of subjects: 58
Study 12601840 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibin A at cut-off value of 1.8 MoM
Number of subjects: 58
Study 12601840 — intervention group
Group type: EXPERIMENTAL
Intervention: Both activin A and inhibin A elevated
Number of subjects: 58
Study 12601840 — intervention group
Group type: EXPERIMENTAL
Intervention: Both hormone markers unaltered
Number of subjects: 58
Study 11099790 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVADs
Number of subjects: 126
Study 8750077 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference assessment and simple, low‐effort treatment procedure
Number of subjects: 15
Study 8750077 — intervention group
Group type: COMPARATOR
Intervention: Chronic training needs group
Number of subjects: 15
Study 8750077 — intervention group
Group type: COMPARATOR
Intervention: Analysis of characteristics of the two groups
Number of subjects: 15
Study 1487623 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromperidol decanoate
Number of subjects: 47
Study 1487623 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine decanoate
Number of subjects: 47
Study 6437707 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant rate enteral nutrition (CREN)
Number of subjects: 0
Study 6437707 — intervention group
Group type: COMPARATOR
Intervention: Fractioned enteral nutrition (FEN)
Number of subjects: 0
Study 31776122 — intervention group
Group type: EXPERIMENTAL
Intervention: Short term exposure to PM2.5 (1 µg/m3 increase)
Number of subjects: 95277169
Study 29396118 — intervention group
Group type: EXPERIMENTAL
Intervention: Primrose intervention (appointments ≤12 with a trained primary care professional)
Number of subjects: 327
Study 29396118 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (feedback of screening results only)
Number of subjects: 327
Study 29396118 — intervention group
Group type: EXPERIMENTAL
Intervention: Primrose intervention
Number of subjects: 327
Study 29396118 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 327
Study 27120082 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg single dose on the evening prior to surgery; 40 mg on the morning of surgery; three further doses of 40 mg on the evenings of postoperative days 0, 1, and 2)
Number of subjects: 200
Study 27120082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 27120082 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 200
Study 27120082 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin and Placebo
Number of subjects: 200
Study 24660950 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-facilitated recovery groups
Number of subjects: 24
Study 24660950 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-facilitated recovery groups
Number of subjects: 24
Study 22356933 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiotic shake containing Lactobacillus acidophilus, Bifidobacterium bifidum, and fructooligosaccharides, 200 mL daily for 30 days.
Number of subjects: 20
Study 22356933 — intervention group
Group type: COMPARATOR
Intervention: Placebo shake without symbiotic bacteria, 200 mL daily for 30 days.
Number of subjects: 20
Study 20606661 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab (biologic therapy)
Number of subjects: 0
Study 20606661 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 17256746 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) added to LAM (n = 28)
Number of subjects: 42
Study 17256746 — intervention group
Group type: COMPARATOR
Intervention: Adefovir dipivoxil (ADV) monotherapy (n = 14)
Number of subjects: 42
Study 16398422 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated traditional and Western medicine (ITWM)
Number of subjects: 324
Study 16398422 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM)
Number of subjects: 324
Study 16398422 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (WM)
Number of subjects: 324
Study 12197792 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulative props
Number of subjects: 54
Study 12197792 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dimensional food portion visuals
Number of subjects: 54
Study 12197792 — intervention group
Group type: COMPARATOR
Intervention: Both measurement aids
Number of subjects: 54
Study 9526923 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of care dimensions including access, appropriateness, technical quality, and the art of care.
Number of subjects: 0
Study 9526923 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assurance guidelines developed by the U.S. Food and Drug Administration and various dental specialties.
Number of subjects: 0
Study 9526923 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical outcomes of treatment and health and well-being measures.
Number of subjects: 0
Study 9526923 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality measurement aspects within a quality assurance program.
Number of subjects: 0
Study 9526923 — intervention group
Group type: EXPERIMENTAL
Intervention: Role of the periodontist in quality of care.
Number of subjects: 0
Study 9526923 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed care implications for quality of periodontal treatment and patient management.
Number of subjects: 0
Study 7652682 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-sewn anastomosis
Number of subjects: 159
Study 7652682 — intervention group
Group type: COMPARATOR
Intervention: Circular stapled anastomosis
Number of subjects: 159
Study 2527699 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory group using meters with inbuilt memories linked to a computer
Number of subjects: 18
Study 2527699 — intervention group
Group type: COMPARATOR
Intervention: Conventional group using diaries to record self‐monitoring meter‐read results
Number of subjects: 18
Study 11277 — intervention group
Group type: EXPERIMENTAL
Intervention: Orphenadrine
Number of subjects: 66
Study 11277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 31248644 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Number of subjects: 125
Study 28094841 — intervention group
Group type: EXPERIMENTAL
Intervention: Pracinostat
Number of subjects: 102
Study 28094841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 26467530 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured follow-up by the GP over a 6-month period with a minimum of five consultations.
Number of subjects: 202
Study 26467530 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured follow-up by the GP
Number of subjects: 202
Study 23434517 — intervention group
Group type: EXPERIMENTAL
Intervention: PAR ablation
Number of subjects: 86
Study 23434517 — intervention group
Group type: COMPARATOR
Intervention: PV isolation
Number of subjects: 86
Study 19956980 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole (400 mg i.v. every 12 h for two doses, followed by 300 mg BID)
Number of subjects: 123
Study 19956980 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole (200 mg i.v. twice daily for 2 days, followed by 200 mg i.v. daily)
Number of subjects: 123
Study 19956980 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 123
Study 19956980 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 123
Study 19375108 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg pentosan polysulfate sodium per day
Number of subjects: 128
Study 19375108 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 128
Study 17343008 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Huoxue Recipe (YHR) combined with polyene phosphatidycholine capsule (PPC)
Number of subjects: 80
Study 17343008 — intervention group
Group type: COMPARATOR
Intervention: Polyene phosphatidycholine capsule (PPC) alone
Number of subjects: 80
Study 16297506 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard diet plus two high-protein/energy supplements containing additional arginine (9 g), vitamin C (500 mg) and zinc (30 mg)
Number of subjects: 16
Study 16297506 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital diet
Number of subjects: 16
Study 16297506 — intervention group
Group type: COMPARATOR
Intervention: Standard diet plus two high-protein/energy supplements
Number of subjects: 16
Study 12235448 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's wort
Number of subjects: 12
Study 12235448 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic oil
Number of subjects: 12
Study 12235448 — intervention group
Group type: COMPARATOR
Intervention: Panax ginseng
Number of subjects: 12
Study 12235448 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo biloba
Number of subjects: 12
Study 9842809 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (Sch) 1.5 mg/kg
Number of subjects: 26
Study 9842809 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium (Roc) 1.2 mg/kg
Number of subjects: 26
Study 7863857 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWL
Number of subjects: 48
Study 7863857 — intervention group
Group type: EXPERIMENTAL
Intervention: PNL
Number of subjects: 48
Study 7863857 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ESWL and PNL
Number of subjects: 48
Study 7863857 — intervention group
Group type: COMPARATOR
Intervention: Control (ESWL)
Number of subjects: 48
Study 2644108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (2 gm intravenously at the beginning of surgery)
Number of subjects: 403
Study 2644108 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (1 gm intravenously at the beginning of surgery and after 3, 6, and 12 hours)
Number of subjects: 403
Study 31119913 — intervention group
Group type: EXPERIMENTAL
Intervention: TECAR
Number of subjects: 48
Study 31119913 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage
Number of subjects: 48
Study 31119913 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure therapy
Number of subjects: 48
Study 31119913 — intervention group
Group type: COMPARATOR
Intervention: Control group (rehabilitation program only)
Number of subjects: 48
Study 28399152 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation programme (n = 9)
Number of subjects: 19
Study 28399152 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 10)
Number of subjects: 19
Study 26188786 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ repair
Number of subjects: 100
Study 26188786 — intervention group
Group type: COMPARATOR
Intervention: Tear completion repair
Number of subjects: 100
Study 23864647 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (184 mg once daily for 7 days post-delivery)
Number of subjects: 72
Study 23864647 — intervention group
Group type: COMPARATOR
Intervention: Control (zidovudine pre-delivery, single-dose nevirapine/zidovudine/lamivudine at delivery and zidovudine/lamivudine for 7 days post-delivery)
Number of subjects: 72
Study 23864647 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 72
Study 23864647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 72
Study 21350434 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylphenidate (MPH)
Number of subjects: 18
Study 21350434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 21350434 — intervention group
Group type: EXPERIMENTAL
Intervention: Food stimuli with MPH
Number of subjects: 18
Study 21350434 — intervention group
Group type: COMPARATOR
Intervention: Food stimuli with Placebo
Number of subjects: 18
Study 19386071 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-level positive airway pressure ventilation (BV)
Number of subjects: 24
Study 19386071 — intervention group
Group type: COMPARATOR
Intervention: Sham ventilation (SV)
Number of subjects: 24
Study 16809647 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-soluble lubricant gel
Number of subjects: 70
Study 16809647 — intervention group
Group type: COMPARATOR
Intervention: No gel (standard of care)
Number of subjects: 70
Study 12518293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (bolus 0.23 mg/kg; 0.5 mg/kg over 45 min to a maximum 1 hr)
Number of subjects: 8
Study 12518293 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline i.v.)
Number of subjects: 8
Study 12518293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine and Placebo
Number of subjects: 8
Study 12020396 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'‐DFUR administered orally for 6 months
Number of subjects: 1217
Study 12020396 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1217
Study 9583665 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (rock music) for a 23-minute session
Number of subjects: 14
Study 9583665 — intervention group
Group type: COMPARATOR
Intervention: Control group (sit and relax for 23 minutes)
Number of subjects: 14
Study 8568186 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal pulse oximetry (Nellcor N-400)
Number of subjects: 0
Study 2203555 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole
Number of subjects: 1112
Study 2203555 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1112
Study 2203555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1112
Study 2203555 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1112
Study 75439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg twice daily)
Number of subjects: 68
Study 75439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 75439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 68